Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCKAR | P32238 | 1/20 | 0.30 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22315954 | 1.00 | TUBB1 (0.48) | TUBB1KDM4EALDH1A1SMN1; SMN2CCKAR | |
| SCHEMBL24574524 | 1.00 | TUBB1 (0.48) | TUBB1KDM4EALDH1A1SMN1; SMN2CCKAR | |
| SCHEMBL22315419 | 0.98 | TUBB1 (0.46) | TUBB1KDM4EALDH1A1SMN1; SMN2CCKAR | |
| SCHEMBL22315422 | 0.98 | TUBB1 (0.46) | TUBB1KDM4EALDH1A1SMN1; SMN2CCKAR | |
| SCHEMBL22315439 | 0.94 | TUBB1 (0.49) | TUBB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20739070 | 0.94 | TUBB1 (0.49) | TUBB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22316494 | 0.93 | TUBB1 (0.47) | TUBB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22315956 | 0.93 | TUBB1 (0.47) | TUBB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22316580 | 0.93 | TUBB1 (0.48) | TUBB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20738990 | 0.93 | TUBB1 (0.48) | TUBB1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TUBB1 119/4885KDM4E 785/4885ALDH1A1 24/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | TUBB1 436/4885KDM4E 574/4885ALDH1A1 1215/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | TUBB1 436/4885KDM4E 574/4885ALDH1A1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.